Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes

OncoImmunology

Volumn 3, Issue 6, 2014, Pages

  Robert, Lidia ^a   Harview, Christina ^a   Emerson, Ryan ^b,c   Wang, Xiaoyan ^a   Mok, Stephen ^a   Homet, Blanca ^a   Comin Anduix, Begonya ^a,d   Koya, Richard C ^a   Robins, Harlan ^b,c   Tumeh, Paul C ^a   Ribas, Antoni ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c ADAPTIVE BIOTECHNOLOGIES   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CTLA 4; MK 3475; PBMC; PD 1; sequencing; TCR; Tremelimumab

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GENOMIC DNA; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR; TICILIMUMAB;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL EXPANSION; GENE AMPLIFICATION; HUMAN; IMMUNOTOXICITY; LYMPHOCYTE PROLIFERATION; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; PERIPHERAL BLOOD MONONUCLEAR CELL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84906510279     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.29244     Document Type: Article

References (10)

1. Robert C, Thomas L, Bondarenko I, O'Day S, M D JW, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-26; PMID:21639810; http://dx.doi. org/10.1056/NEJMoa1104621
2. Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013; 31:616-22; PMID:23295794; http://dx.doi.org/10.1200/JCO.2012.44.6112
3. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
4. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134-44; PMID:23724846; http://dx.doi. org/10.1056/NEJMoa1305133
5. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32:1020-30; PMID:24590637; http:// dx.doi.org/10.1200/JCO.2013.53.0105
6. Ribas A, Comin-Anduix B, Chmielowski B, Jalil J, de la Rocha P, McCannel TA, Ochoa MT, Seja E, Villanueva A, Oseguera DK, et al. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res 2009; 15:6267-76; PMID:19789309; http://dx.doi. org/10.1158/1078-0432.CCR-09-1254
7. Comin-Anduix B, Lee Y, Jalil J, Algazi A, de la Rocha P, Camacho LH, Bozon VA, Bulanhagui CA, Seja E, Villanueva A, et al. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med 2008; 6:22; PMID:18452610; http:// dx.doi.org/10.1186/1479-5876-6-22
8. Robert L, Tsoi J, Wang X, Emerson R, Homet B, Chodon T, Mok S, Huang RR, Cochran AJ, Comin- Anduix B, et al. CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res 2014; 20:2424-32; PMID:24583799; http://dx.doi. org/10.1158/1078-0432.CCR-13-2648
9. Robins HS, Campregher PV, Srivastava SK, Wacher A, Turtle CJ, Kahsai O, Riddell SR, Warren EH, Carlson CS. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood 2009; 114:4099-107; PMID:19706884; http://dx.doi.org/10.1182/blood-2009-04-217604
10. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/ PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 2013; 19:5300-9; PMID:24089443; http://dx.doi.org/10.1158/1078-0432.CCR-13-0143